Avid Bioservices Inc (CDMO)

[entdoc]

Bavituximab is PPHM flagship, but just as Microsoft/Google/Apple CEOs have said they are looking for new CATEGORY entries which create a market for related spinoffs, ANTI-PS is a new category in biotech. I would be terribly disappointed if Bavi does not make the grade, but it would not surprise me if a month before or after that decision there appeared confirmation of an equally impactful application of anti-PS, and it will probably be in the realm of inflammation and infectious disease, but could be as disparate as vasculitis or Alzheimer's disease. I hope Bavi is approved, but find it difficult to believe that Bavi vs. incurable bulky solid cancers is the best and highest (and only) application of PPHM's anti-PS patents. To feel reassured, simply read the patents. I'm still on board. Haven't bought much lately though. Cheers! And have a great weekend. It is sunny and warm in Carmel.